[Ip-health] 2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors | Knowledge Ecology International

Jamie Love james.love at keionline.org
Mon Jul 31 07:49:54 PDT 2017


https://www.keionline.org/node/2795

This is part of an exchange with the NIH over the prospective grant of an
exclusive license for Mutant IDH1 Inhibitors Useful for Treating Cancer,
and it illustrates
​a typical exchange with the NIH, which is to say, 1.  they won't talk
about pricing, 2. they won't answer questions about the technology or the
NIH role in its funding (including going forward), and ​3. They won't
answer questions about the company getting the license.


​As reported in the URL above, t​
he KEI letter make three asks:

1. KEI proposed that the license include provisions to address pricing,
including specifically:

"The [agency] will normally expect the licensee to make products available
to the public in the United States at prices no higher than the median
price charged in the seven countries with the largest GDP, that have per
capita incomes of at least half that of the United States. "

And left open the possibility of additional language dealing with access in
developing countries.

2.  KEI wanted a call to learn more about the technology being licensed and
asked about the NIH role in funding the development of the technology.

3.  KEI asked if the company seeking the license was a subsidiary of a
company with its head office in Geneva Switzerland.

​Also included in the URL above is the
July 18, 2017
​ response by the
NIH
​ to our three issues/questions.

​The exact ​
N
​IH responses were:

​
1.  Response: “With respect to your recommendations regarding pricing of
products made by the licensee, NIH has not included pricing provisions in
its licenses for many years, for reasons that have been extensively
discussed in the literature, which is readily and publicly available.”

2.  Response: “The technology is thoroughly described in the published
scientific articles and patent application, which can be found by following
these links: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922311/ and
http://www.freepatentsonline.com/y2014/0296241.html. I do not have any
information on funding.”

3.  Response: As stated in the notice, the intent is to grant the license
to GeneXion Oncology, Inc., located in New York, NY.



More information about the Ip-health mailing list